Loxapine

Loxapine

SCHEMBL30201498

CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1.O=C(O)CCC(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

DRD2DRD3DRD4HTR2AHTR2C

The experimentally established mechanism targets of Loxapine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD4 known ✓ P21917 6/20 0.82
DRD2 known ✓ P14416 6/20 0.82
DRD3 known ✓ P35462 6/20 0.82
HTR2A known ✓ P28223 4/20 0.82
HTR2C known ✓ P28335 4/20 0.82
LMNA P02545 3/20 1.00
MEN1 O00255 2/20 1.00
CYP1A2 P05177 2/20 1.00
CYP3A4 P08684 2/20 1.00
CYP2D6 P10635 2/20 1.00
PMP22 Q01453 2/20 1.00
KMT2A Q03164 2/20 1.00
SMN1; SMN2 Q16637 2/20 1.00
ABCB11 O95342 1/20 1.00
CYP2C9 P11712 1/20 1.00
BLM P54132 1/20 1.00
HRH4 Q9H3N8 11/20 0.82
CHRM1 P11229 5/20 0.82
HRH1 P35367 4/20 0.82
ADRA2A P08913 4/20 0.82

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Loxapine SCHEMBL5500954 1.00 LMNA (1.00) LMNAMEN1CYP1A2CYP3A4CYP2D6
Loxapine SCHEMBL29414130 1.00 LMNA (1.00) LMNAMEN1CYP1A2CYP3A4CYP2D6
Loxapine SCHEMBL41643 1.00 LMNA (1.00) LMNAMEN1CYP1A2CYP3A4CYP2D6
Loxapine SCHEMBL29482385 0.90 HRH4 (1.00) LMNAMEN1CYP1A2CYP3A4CYP2D6
Loxapine SCHEMBL30324780 0.90 HRH4 (1.00) LMNAMEN1CYP1A2CYP3A4CYP2D6
Loxapine SCHEMBL29374082 0.90 HRH4 (1.00) LMNAMEN1CYP1A2CYP3A4CYP2D6
Loxapine SCHEMBL19386241 0.90 HRH4 (1.00) LMNAMEN1CYP1A2CYP3A4CYP2D6
Loxapine SCHEMBL94146 0.90 HRH4 (1.00) LMNAMEN1CYP1A2CYP3A4CYP2D6
Loxapine SCHEMBL41644 0.90 LMNA (0.82) LMNAMEN1CYP1A2CYP3A4CYP2D6
SCHEMBL5946392 0.90 MEN1 (0.81) LMNAMEN1CYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026106958-A1 SOFT MIST INHALER AND IMPROVEMENTS THEREFOR Transpire Bio Inc. (US) 2026-05-21 WO disclosed
US-20250197527-A1 STABLE HETERODIMERIC ANTIBODY DESIGN WITH MUTATIONS IN THE Fc DOMAIN ZYMEWORKS BC INC. (CA) 2025-06-19 US disclosed
US-20250034251-A1 ANTIBODY CHEMICALLY INDUCED DIMERIZER (ABCID) AS MOLECULAR SWITCHES FOR REGULATING CELLULAR THERAPIES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2025-01-30 US disclosed
US-12162955-B2 CBX8 chromdomain inhibitors and the uses thereof PURDUE RESEARCH FOUNDATION (US) 2024-12-10 US disclosed
US-11939379-B2 Antibody chemically induced dimerizer (AbCID) as molecular switches for regulating cellular therapies THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-03-26 US disclosed
US-20230348846-A1 ENGINEERED CELLS AND METHODS OF USE THE SCRIPPS RESEARCH INSTITUTE 2023-11-02 US disclosed
US-11753619-B2 Engineered cells and methods of use THE SCRIPPS RESEARCH INSTITUTE (US) 2023-09-12 US disclosed
US-20230257421-A1 CBX8 CHROMDOMAIN INHIBITORS AND THE USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-08-17 US disclosed
US-11566046-B2 CBX8 chromdomain inhibitors and the uses thereof PURDUE RESEARCH FOUNDATION (US) 2023-01-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230257421-A1 CBX8 CHROMDOMAIN INHIBITORS AND THE USES THEREOF CBX8, CBX3, CBX2 DRD4 4574/4885DRD2 4555/4885DRD3 3953/4885
US-20250034251-A1 ANTIBODY CHEMICALLY INDUCED DIMERIZER (ABCID) AS MOLECULAR SWITCHES FOR REGULATING CELLULAR THERAPIES BID, BAD, BCL2L10 DRD4 1022/4885DRD2 552/4885DRD3 449/4885
US-11566046-B2 CBX8 chromdomain inhibitors and the uses thereof CBX8, CBX3, CBX2 DRD4 4574/4885DRD2 4555/4885DRD3 3953/4885
US-11939379-B2 Antibody chemically induced dimerizer (AbCID) as molecular switches for regulating cellular therapies BID, BAD, BCL2L10 DRD4 1022/4885DRD2 552/4885DRD3 449/4885
US-12162955-B2 CBX8 chromdomain inhibitors and the uses thereof CBX8, CBX3, CBX2 DRD4 4574/4885DRD2 4555/4885DRD3 3953/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.